Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

5 Customer Reviews

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NXTlUGt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX6OYU2yqEQvF2= NHXZ[Fg1QMLiaB?= MnWwZoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ M3uwWFI3OzVyNU[1
NP69 NW\Qdlk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M322RWlEPTB;M{GuOlnDuTJwNUSg{txO M{PUblI3OjV{NUe1
NP460 NEjWOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ{Lki1xtEyNjF6IN88US=> M4TDPFI3OjV{NUe1
C666-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXiUJZWUUN3ME2xPU46PcLzOD65N{DPxE1? MVqyOlI2OjV5NR?=
C666-1 NW\zV3ZXS2WubDDWbYFjcWyrdImgRZN{[Xl? MmPxNVAhyrWP MWS0PEBp NX62ZVBNTE2VTx?= M4\mc5NmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= MYeyOlI2OjV5NR?=
C666-1  NF:yTIpHfW6ldHnvckBCe3OjeR?= MlLCNVAhyrWP M17TcFI1KGh? NFP3U|hFVVOR Ml3EZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z M{PKXlI3OjV{NUe1
C666-1 NIm1dHFCeG:ydH;zbZMhSXO|YYm= NXrz[WY5OTBiwsXN MXO0PE84OiCq MVfEUXNQ MYXz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= NFXzUm0zPjJ3MkW3OS=>
A549 M1vIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyOEBp MnPVTWM2OD1zNz62PEDDuSB2LkWyJO69VQ>? NIrzZ4szPjF{NUKzNC=>
A549-NTC M3fpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[4d4ZiOjRiaB?= NYDZOXNnUUN3ME2xPU41OiEEsTCxMlk3KM7:TR?= NHLYc3kzPjF{NUKzNC=>
A549-920 NH3JbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HFUVI1KGh? NX2zeYtmUUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= M16zR|I3OTJ3MkOw
CRL-5908 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjSNXJDOjRiaB?= MXHJR|UxRTN6LkexJOKyKDJwNEOg{txO MmT4NlYyOjV{M{C=
L6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNOKh|ryPwrC= NEi2SpkzPC92OD:3NkBp M3rHc2ROW09? MoTHbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v MWKyOVg4OTd7NB?=
C2C12 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHONVDDqM7:TdMg M4DFTFI1NzR6L{eyJIg> MW\EUXNQ NGe4OHFqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? NEnHRYEzPTh5MUe5OC=>
MCF-7  NEn1NpRHfW6ldHnvckBCe3OjeR?= NHrVZogyOMLizszN NGC5eIlFVVOR M3nMOYlvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? NGDDepgzPTdyMkewNy=>
DU4475  MnLXSpVv[3Srb36gRZN{[Xl? NHLTZZY2NzFyL{KwJO69VQ>? MoLsNlTDqGh? NX3iZVEz\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>? MYeyOVU1PzF5NB?=
SMMC-7721 MoXuSpVv[3Srb36gRZN{[Xl? MYOxNEDPxE1? MWe0PEBp M{iydGROW09? MUfjZZV{\XNiRF7BJGRUSiCmYX3h[4U> NHLwe5EzPTV2NEO2NS=>
SMMC-7721 MWXGeY5kfGmxbjDBd5NigQ>? NXW4Onh2OTBizszN M2TjfVQ5KGh? NXjqeGRNTE2VTx?= M1jQTolv\HWlZYOgeIhmKGOqcn;tZZRqdi2kb4Xu[EBxem:2ZXnuJGlHUTF4IITvJJBienSrYXzsfUBtd2OjbHn6[UBqdiC2aHWgZ5l1d3CuYYPtxsA> NVm5SmU4OjV3NESzOlE>
SMMC-7721 MXnGeY5kfGmxbjDBd5NigQ>? NVm5OndOOTBizszN NVW1NVlOPDhiaB?= NFXQ[GFFVVOR MWPpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B M1qyNFI2PTR2M{[x
SMMC-7721 NUDRUoV[TnWwY4Tpc44hSXO|YYm= NHnyOmgyOCEQvF2= MkjNN|YhcA>? MXfEUXNQ M4XOV4NifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 M{DzcVI2PTR2M{[x
MCF-7 NWfsOZVlTnWwY4Tpc44hSXO|YYm= MoPmNVDDqM7:TR?= MlS0NE0zPCCq M1P6dolv\HWlZYOgdFU{KGGwZDDwNlEwS2myMR?= NV36RoVHOjV2OEKzO|M>
OVCAR10 M4X3SmZ2dmO2aX;uJGF{e2G7 MWmxNOKh|ryP NYO1fFlIOjGqwrC= MWLEUXNQ M2HDW4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MUiyOVQzPjV2OB?=
NCI-H23 NWLQd49zTnWwY4Tpc44hSXO|YYm= MYGxNOKh|ryP MkLsNlFpyqB? NIro[JNFVVOR NWLzc49QcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NYGwSFN{OjV2Mk[1OFg>
A2780 M2TabGZ2dmO2aX;uJGF{e2G7 NH7TV2wyOMLizszN NX;P[ZdUOjGqwrC= NULYW|VHTE2VTx?= NUm5VoxrcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MVOyOVQzPjV2OB?=
NCI-H23 NVTUNox7TnWwY4Tpc44hSXO|YYm= NIrtWpMyOMLizszN M3fWclIycMLi NXWxc5J7TE2VTx?= MWLk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MnfLNlU1OjZ3NEi=
A2780 NF3wNI1HfW6ldHnvckBCe3OjeR?= MXuxNOKh|ryP MYOyNYjDqA>? NYiwenBHTE2VTx?= M3[0[IRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz MYCyOVQzPjV2OB?=
HCT116  MnjBSpVv[3Srb36gRZN{[Xl? NFLJV4gyOCEEtV2= MWWyOEBp NICyVW1k[XW|ZYOgZUBxPTNvZHXw[Y5l\W62IITleJJieGyxaXSgS|Eu[XK{ZYP0JIlvKGSrcHzvbYQhUEOWMUG2JINtd26nczDEN{BidmRiREi= MUKyOVM5ODB3NR?=
MCF-10CA1a MXjGeY5kfGmxbjDBd5NigQ>? NInnNJgyOMLizszN MWC0PEBp MoToSG1UVw>? MVXpcohq[mm2czDiZZNidCCrbo\hd4lwdiCjbnSgdoVlfWOnZDDUS2Yu|rJ|LXnu[JVk\WRiaX72ZZNqd25idH:gZoF{[WxibHX2[Yx{ NVHLU5RwOjV{NUe3Nlk>
MCF-10A1  Ml\uSpVv[3Srb36gRZN{[Xl? M1vrRlExyqEQvF2= NXTLd4U2OjRxNEigbC=> MnjOSG1UVw>? NYPJXpUzcW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi MXSyOVI2Pzd{OR?=
MCF-10CA1a NV\xN204TnWwY4Tpc44hSXO|YYm= NFG0cWcyOMLizszN M3;YelI1KGh? MnnWSG1UVw>? MYnk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? MlrlNlUzPTd5Mkm=
MCF-10CA1a NVPlN5luTnWwY4Tpc44hSXO|YYm= M1:3UFExyqEQvF2= NWfvVZAyOjRiaB?= M1;C[mROW09? MVfpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M1rHWVI2OjV5N{K5
SK-BR-7 NXzYTosxTnWwY4Tpc44hSXO|YYm= MmDnNVDDqM7:TR?= NXrKT2F5OjRiaB?= NV\KS4RoTE2VTx?= MXzpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NGO5bGgzPTJ3N{eyPS=>
SUM102PT Mm\3SpVv[3Srb36gRZN{[Xl? M1rsSVExyqEQvF2= MUOyOEBp M3n0W2ROW09? NGrvd2ZqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MmrXNlUzPTd5Mkm=
RAW 264.7 MUTGeY5kfGmxbjDBd5NigQ>? MYexNOKh|ryP M{\MN|MxKG2rbh?= NHvyfW5xemW4ZX70d{B1cGVicEWzJJJm\HWldHnvckBqdiC{ZYPwc45{\SC2bzDMVHM> MV6yOVE4OjV2Nx?=
RAW 264.7 MVHGeY5kfGmxbjDBd5NigQ>? MYWxNOKh|ryP NV3IcGVxOzBibXnu NUS1c4ROemWmdXPld{B1cGViTGDTMYF2\22nboTl[EB1cGViTl[t{tpDKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi[3Srdnn0fS=> NWPhcZMyOjVzN{K1OFc>
RAW 264.7 NHfJeZlHfW6ldHnvckBCe3OjeR?= Mor3NVDDqM7:TR?= M{\NPFMxKG2rbh?= NHHUW3NqdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> M4LwflI2OTd{NUS3
MCF7  NV3NS2FTS2WubDDWbYFjcWyrdImgRZN{[Xl? NV\VXVM1Oi53INM1US=> NIPpPJc2KGR? MojJSG1UVw>? NEnuZYJ{\W6|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u NFHTdFgzPTB6NUmwNi=>
MCF7  MVrGeY5kfGmxbjDBd5NigQ>? M1vVPVIvPSEEtV2= NUjKdFJCPDhiaB?= M{D0Z2ROW09? NYDifI5F\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? MkHuNlUxQDV7MEK=
ACHN M2fZPGNmdGxiVnnhZoltcXS7IFHzd4F6 NV7jT3V4OC53LUGwJO69VQ>? NXfKR4RpOC14IHS= MU\EUXNQ MU\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYGyOVA3Pzd6Nx?=
Caki-2 MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUnG[m5[OC53LUGwJO69VQ>? M3jH[|AuPiCm MnjRSG1UVw>? MX7pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4TZXVI2ODZ5N{i3
A498 NXrBTWlVS2WubDDWbYFjcWyrdImgRZN{[Xl? MX:wMlUuOTBizszN NIDmfnoxNTZiZB?= MXnEUXNQ MVrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEfZWpEzPTB4N{e4Oy=>
115 Mn7yR4VtdCCYaXHibYxqfHliQYPzZZk> MUCwMlUuOTBizszN NUnhS2xyOC14IHS= NIm0TWxFVVOR NF3LdI1qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2XuZVI2ODZ5N{i3
117 NG\iT2tE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MonqNE42NTFyIN88US=> M4LKRVAuPiCm M1;CVmROW09? M{T2TIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2K3dFI2ODZ5N{i3
ACHN M{LMVGZ2dmO2aX;uJGF{e2G7 MVOwMlUwOS93IN88US=> MV:0PEBp NVnaVpNNTE2VTx?= M1LYUIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NEnDW2MzPTB4N{e4Oy=>
Caki-2 M{DzTWZ2dmO2aX;uJGF{e2G7 MnnENE42NzFxNTFOwG0> MXi0PEBp NUfxOphDTE2VTx?= MYPs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MV2yOVA3Pzd6Nx?=
A498 M{jHOGZ2dmO2aX;uJGF{e2G7 M4j6dlAvPS9zL{Wg{txO M{KzfFQ5KGh? MlnCSG1UVw>? NX[1[IxtdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= MVSyOVA3Pzd6Nx?=
115 NHHtXmJHfW6ldHnvckBCe3OjeR?= MWOwMlUwOS93IN88US=> MlSzOFghcA>? NH3CXpNFVVOR MXns[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NHvKdVUzPTB4N{e4Oy=>
ACHN NUXzV4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\tPZJ5PSEQvF2= NHz5dHM1QCCq NF;NemZFVVOR MYjpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NXfSN3J{OjVyNke3PFc>
Caki-2 M4ewUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:1JO69VQ>? NF3mbYc1QCCq NWLTTHI6TE2VTx?= MYnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NVv0VGNnOjVyNke3PFc>
A498 M3HMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi2VGU2KM7:TR?= NYTnVo1nPDhiaB?= NIjidpRFVVOR M2XIXYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MX[yOVA3Pzd6Nx?=
115 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M324b|Uh|ryP NYnxWIFDPDhiaB?= M4\iR2ROW09? M{PlZ4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MW[yOVA3Pzd6Nx?=
ACHN Mn;QSpVv[3Srb36gRZN{[Xl? MVW1JO69VQ>? NYTNNYFPPDhiaB?= NH;QR5BFVVOR NXPPVlZncW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MnrpNlUxPjd5OEe=
Caki-2 Ml7MSpVv[3Srb36gRZN{[Xl? MXW1JO69VQ>? MnrnOFghcA>? MXzEUXNQ MnLBbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NX3qXYZKOjVyNke3PFc>
A498 NHv5bHdHfW6ldHnvckBCe3OjeR?= NXjRcVZ7PSEQvF2= NGfxbXI1QCCq M1zmSWROW09? MnftbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= M3i0TFI2ODZ5N{i3
115 M1riNGZ2dmO2aX;uJGF{e2G7 NV\3[IxiPSEQvF2= NGHSWlY1QCCq MVrEUXNQ NXHNS29wcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NUjOW5BxOjVyNke3PFc>
MOLM-13 NYDGR4F{TnWwY4Tpc44hSXO|YYm= NYnnTnp3PsLizszN NGnnOWkxNThiaB?= MWjEUXNQ MUXpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyNUOsJG1FVTJuIICyNUBidmRiYXPleJlt[XSnZDDwOVM> NIrDZ20zPDh6NUC4Ni=>
MOLM-13 NY\qV3dqTnWwY4Tpc44hSXO|YYm= MmHhOuKh|ryP MV62JIg> MXnEUXNQ MlzC[Y5p[W6lZYOgeIhmKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFJDKGGwZDDo[YF1KHOqb3PrJJBzd3SnaX7zJGh{eDJ5IHHu[EBJe3B7MB?= MlfpNlQ5QDVyOEK=
HepG2 M4racGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nXc|czKGh? M3LiO2ROW09? NF;sWm1KSzVyPUO1Mlg3KMLzIEKuPUDPxE1? NEfmN5UzPDh6NEiwPS=>
HepG2/As NYS5enN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoixO|IhcA>? M3fNemROW09? MmDoTWM2OD14OD6xN{DDuSB7Lk[g{txO NYj6bVBGOjR6OES4NFk>
SMMC7721 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK3NkBp NYXBSHQ4TE2VTx?= MlfnTWM2OD1|MT6yPEDDuSB2LkKg{txO NUHw[ll5OjR6OES4NFk>
SMMC7721/Ac M2T3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rpOFczKGh? MmjTSG1UVw>? M1zaOGlEPTB;NUWuNlEhyrFiNT6wN{DPxE1? NWm0NllpOjR6OES4NFk>
Huh-7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK4UFg4OiCq NXv0dm97TE2VTx?= M3\xb2lEPTB;M{OuPVYhyrFiMz65JO69VQ>? MV[yOFg5PDhyOR?=
Hep3B Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu3NkBp MXnEUXNQ MXzJR|UxRTJyLkG4JOKyKDFwOESg{txO MYiyOFg5PDhyOR?=
HepG2 NWryXlB4SXCxcITvd4l{KEG|c3H5 MoTsbY5lfWOnczDhdI9xfG:|aYO= NYDjZVdIOjR6OES4NFk>
SMMC7721 NFPtWYFCeG:ydH;zbZMhSXO|YYm= NVPV[|FjcW6mdXPld{BieG:ydH;zbZM> MXeyOFg5PDhyOR?=
Huh-7 MX3BdI9xfG:|aYOgRZN{[Xl? MYnpcoR2[2W|IHHwc5B1d3Orcx?= NIXFUXQzPDh6NEiwPS=>
Hep3B MkLxRZBweHSxc3nzJGF{e2G7 MUjpcoR2[2W|IHHwc5B1d3Orcx?= NFHrUGozPDh6NEiwPS=>
U2OS  NHfCTphHfW6ldHnvckBCe3OjeR?= NIrqeGUzOCEQvF2= MoPXNlQhcA>? M2LiU4lv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= Mnr3NlQ5Pjd{NUm=
AML2 NWHPeVRVSXCxcITvd4l{KEG|c3H5 MmXKNk8yOCEQvF2= NIDjWIMzPC92ODDo NYX5b5RkcW6mdXPld{BieG:ydH;zbZM> MlvrNlQ3PTl5NEm=
MOML13 MV\BdI9xfG:|aYOgRZN{[Xl? NWD3cXppOi9zMDFOwG0> M1u4RVI1NzR6IHi= NGnzNYpqdmS3Y3XzJIFxd3C2b4Ppdy=> NVPPflU3OjR4NUm3OFk>
AML2 MV3GeY5kfGmxbjDBd5NigQ>? MXKxNO69VQ>? MYKyM|QhcA>? M2XVSIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz MUeyOFY2QTd2OR?=
AML3 NUL0To11TnWwY4Tpc44hSXO|YYm= MmCzNVDPxE1? MXmyM|QhcA>? MVnpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= M1;xd|I1PjV7N{S5
MOML13 M3\aRmZ2dmO2aX;uJGF{e2G7 MXWxNO69VQ>? MUCyM|QhcA>? NUD6eodocW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> Mn;iNlQ3PTl5NEm=
BeWo MnnGSpVv[3Srb36gRZN{[Xl? MVOzNEDDvU1? NIrjT24zPCCq NEjIVHpqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> MUSyOFQ6QDF3NB?=
BeWo NIjudVhCeG:ydH;zbZMhSXO|YYm= MluxN|AhyrWP M1LifFI1KGh? Mn;qbY5kemWjc3XzJIFxd3C2b4Ppdy=> NGHzPFgzPDR7OEG1OC=>
OCI NUn0XVV2TnWwY4Tpc44hSXO|YYm= M{jBWFExKM7:TR?= MWqyOEBp NUDyS2l7fXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u MYOyOFQ4OzV4Mh?=
MOLM MXPGeY5kfGmxbjDBd5NigQ>? NX\aN5pPOTBizszN MUmyOEBp NIDFbmR2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= M1HkRlI1PDd|NU[y
U2OS  MnLxSpVv[3Srb36gRZN{[Xl? MY[yNEDPxE1? NX3XZYx[OjRiaB?= MWfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv Mo[5NlQ{PjZyMEe=
RKO MV7GeY5kfGmxbjDBd5NigQ>? NI\sdmozOCEQvF2= NIPCcZkzPCCq MUDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv MkDxNlQ{PjZyMEe=
U2OS  M1:0U2Z2dmO2aX;uJGF{e2G7 M4WyNlIxKM7:TR?= NUT3bGFzOjRiaB?= MmHXbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MWeyOFM3PjByNx?=
RKO NWPHdppqTnWwY4Tpc44hSXO|YYm= M2fKTVIxKM7:TR?= MnqzNlQhcA>? Mnz5bY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MlvuNlQ{PjZyMEe=
SMMC-7721  NI\VNIlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWLYVIg2OS5{NT2yNEDPxE1? NHW4bnozPC92OD:3NkBp NHfYfIpFVVOR NH[2[ZZqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MkjtNlQzQDZ|MUK=
HuH-7 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmHWNU4zPS1{MDFOwG0> NFq1[W0zPC92OD:3NkBp NEjYNYdFVVOR MUXpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= M1XEOVI1Ojh4M{Gy
SMMC-7721  MWLBdI9xfG:|aYOgRZN{[Xl? NWLBTZJGOjBizszN NEXVbYo1QCCq MUPEUXNQ NF;sdWFqdmS3Y3XzJIFxd3C2b4Ppdy=> NEHBOGMzPDJ6NkOxNi=>
HuH-7 NH;kNINCeG:ydH;zbZMhSXO|YYm= NXT3N4VQOjBizszN MWS0PEBp NUW2cpJNTE2VTx?= M4fDXIlv\HWlZYOgZZBweHSxc3nz MVuyOFI5PjNzMh?=
SMMC-7721  M4[5U2Z2dmO2aX;uJGF{e2G7 NEHmR2gyOCEQvF2= MWezOkBp Mk\PSG1UVw>? MUjkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> MnL3NlQzQDZ|MUK=
HuH-7 M3nhU2Z2dmO2aX;uJGF{e2G7 M3[3RVExKM7:TR?= NYnKRoZvOzZiaB?= M1O4SWROW09? NWnSOnpn\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? MoHGNlQzQDZ|MUK=
AT2 MYfGeY5kfGmxbjDBd5NigQ>? MUC1M|ExKM7:TR?= MW\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? MYqyOFI1ODJyMx?=
REH M1TIV2Z2dmO2aX;uJGF{e2G7 MWi1M|ExKM7:TR?= MYfs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? M4j6XlI1OjRyMkCz
UoCB6 NFzaOHdHfW6ldHnvckBCe3OjeR?= NXPCNHdHPS9zMDFOwG0> NGfBWWVt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NEXGbYEzPDJ2MEKwNy=>
AT2 MkT5R4VtdCCYaXHibYxqfHliQYPzZZk> M3XmflAuOjVizszN MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NWX5UIpmOjR{NECyNFM>
REH NUXNTZk1S2WubDDWbYFjcWyrdImgRZN{[Xl? M4XUdlAuOjVizszN MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 Mn7qNlQzPDB{MEO=
UoCB6 NH:zSHlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1LsSVAuOjVizszN MYTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXXESVFxOjR{NECyNFM>
A2780 NEnoOm5HfW6ldHnvckBCe3OjeR?= NUD5dpQ3PS9zMD:yNEDPxE1? NGTlToIzPCCq NEeyVGV2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MV6yOFE{PjF2Nx?=
H460 NV\KTHdxTnWwY4Tpc44hSXO|YYm= NH62dW82NzFyL{KwJO69VQ>? NF;meFQzPCCq NVO3Wms6fXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= M1vrZ|I1OTN4MUS3
Lovo  NXThfZk6TnWwY4Tpc44hSXO|YYm= MYi1M|ExNzJyIN88US=> NF7ydXgzPCCq NH31WnJ2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NWXkPXVZOjRzM{[xOFc>
A2780 MUjBdI9xfG:|aYOgRZN{[Xl? MYm1M|ExNzJyIN88US=> Mn3LNlQhcA>? NFLWd|dmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? MWSyOFE{PjF2Nx?=
H460 MXTBdI9xfG:|aYOgRZN{[Xl? Mn7MOU8yOC9{MDFOwG0> MYGyOEBp MWLlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> M{KxR|I1OTN4MUS3
Lovo  NHjwcJBCeG:ydH;zbZMhSXO|YYm= MWe1M|ExNzJyIN88US=> NI\ySmIzPCCq M{P3[4VvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN M13Ge|I1OTN4MUS3

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MDM2 / p53 / ALKBH2 / p21 / PUMA; 

PubMed: 23258843     


CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting.

RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; 

PubMed: 28507282     


(A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.

23258843 28507282
Immunofluorescence
Lamin A / Lamin C / p16 / H3K9me3; 

PubMed: 30728349     


c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. 

Merlin / cyclin D1 / p53 / MDM2; 

PubMed: 30274821     


The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm.

p53; 

PubMed: 24286312     


The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).

30728349 30274821 24286312
Growth inhibition assay
Cell viability; 

PubMed: 29286113     


Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.

29286113
In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID